News
See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.
Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease ...
Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2023, it had a debt/adjusted EBITDA ratio of 0.42 times and over JPY 1.2 trillion in ...
An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...
(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...
Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion.
Three years earlier, Daiichi Sanko snapped up Germany’s U3 Pharma for €150 million ($235 million at the time but $190.5 million today). That deal boosted Daiichi Sankyo’s pipeline with U3 ...
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...
Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and UC San Francisco (UCSF) have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for ...
Daiichi Sankyo Co. has agreed to buy Ambit Biosciences for about $315 million, pointing to the potential of Ambit's drug candidate quizartinib, which is in late-stage trials for the treatment of ...
MarketWatch.com AstraZeneca, Daiichi Sankyo in $6B oncology deal By Adria Calatayud Published: July 27, 2020, 2:24 a.m. ET Share ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results